Monoclonal antibody-based therapy of neuroblastoma.
The curative potential of mAbs in the treatment of patients with metastatic neuroblastoma is increasingly evident. The idiotype network appears to represent one component of a complex mechanism for success with mAb-based immunotherapy. Ongoing strategies to modify or reconstruct mAbs, to engage them with cytokines, or to unite them with T cells open new avenues for harnessing the unique forces of the immune system against some of the most deadly pediatric cancers.
Cheung
N K
NK
Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. cheungn@mskcc.org
Kushner
B H
BH
Kramer
K
K
D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods*; D009447:Neuroblastoma / Q000188:drug therapy* / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal